Whitehead Institute researchers reported a genome-wide screening platform to identify modifications in producer cells that improve the production and delivery potency of engineered virus-like particles carrying gene-editing payloads. The Nature Communications study mapped which host genes drive or block eVLP assembly and found that adjusting producer-cell biology can boost guide RNA generation and functional particle output. The approach extends across different gene-editing tools and delivery vehicle systems, addressing a key bottleneck in gene editing therapeutics: not only delivering the editing machinery safely, but manufacturing delivery vehicles with sufficient potency. For the broader field, the work provides a practical framework for improving both scalability and delivery performance, which can be decisive for moving from preclinical proof-of-concept to clinical translation.